据招股书，2023年-2024年，京新药业实现收入分别为40亿元、41.59亿元；年内溢利分别为6.23亿元、 7.19亿元。 2025年前10个月，公司实现收入为33.44亿元，同比减少2.74%；期内溢利为6.29亿元，同比增长 12.69%。 | | 截至12月31日止年度 | | 截至10月31日止十個月 | | | --- | --- | --- | --- | --- | | | 2023年 | 2024年 | 2024 年 | 2025年 | | | | | (未經審核) | | | | | (人民幣千元) | | | | 收入 | 3.998.835 | 4.158.551 | 3.438.388 | 3.344.144 | | 銷售成本 | (2,032,050) | (2,143,031) | (1,757,318) | (1,730,246) | | 毛利 | 1.966.785 | 2.015.520 | 1.681.070 | 1.613.898 | | 其他收入 | 118.741 | 184.443 | 143,423 | 89.798 | | 预期信貸虧損模式項下的 | | | ...

（文章来源：证券日报） 证券日报网讯 2月26日，京新药业在互动平台回答投资者提问时表示，公司会努力做好市值管理工作， 向投资者正确传达公司的经营情况和临床试验进展。 ...

Core Viewpoint - Zhejiang Jingxin Pharmaceutical Co., Ltd. has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor, focusing on innovation-driven pharmaceutical development in central nervous system and cardiovascular diseases [3]. Financial Performance - The company projects revenues of RMB 4 billion and RMB 4.16 billion for 2023 and 2024, respectively, with net profits of RMB 623 million and RMB 719 million for the same years [4]. - For the first ten months of 2025, the company reported revenues of RMB 3.34 billion, a decrease of 2.74% year-on-year, while net profit increased by 12.69% to RMB 629 million [3][4]. Business Model - Jingxin Pharmaceutical's business model combines the commercialization of existing products with the ongoing development of its product pipeline, which includes a range of pharmaceuticals, active pharmaceutical ingredients, and medical devices [3]. Shareholding Structure - The company is controlled by a group of shareholders led by Executive Director and Chairman Lv Gang, who directly holds approximately 20.77% of the company, while Jingxin Holdings and Jinzhihua Investment hold 15.68% and 51% of Jingxin Holdings, respectively [5]. Leadership - Lv Gang, aged 63, has been with the company since 1999 and has held various leadership roles, including Executive Director and General Manager, responsible for strategic planning and overall operations [9][10]. - Hong Yunfei, aged 46, joined the company in 2005 and is currently the Executive Director and Secretary of the Board, overseeing strategic investments and chemical research [11].

（文章来源：每日经济新闻） 京新药业（002020.SZ）2月26日在投资者互动平台表示，盐酸卡利拉嗪胶囊正在推进其审评工作，暂未 收到批准上市的批文。 每经AI快讯，有投资者在投资者互动平台提问：盐酸卡利拉嗪胶囊评审公示已经撤除，是不是评审阶 段已经结束，等待批文？ ...

证券代码：002020 证券简称：京新药业 公告编号：2026014 浙江京新药业股份有限公司 关于更换持续督导保荐代表人的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 本次保荐代表人变更后，公司 2020 年度非公开发行股票的持续督导保 荐代表人为朱翔坚、龙佳喜，持续督导责任截至募集资金使用完毕为止。 本次变更不影响平安证券对公司的持续督导工作，公司董事会对汪颖女 士在担任公司保荐代表人期间所做的工作表示衷心感谢！ 特此公告。 浙江京新药业股份有限公司董事会 2026 年 2 月 24 日 附件：龙佳喜先生简历 龙佳喜先生，金融学硕士，保荐代表人，现任平安证券投资银行事业部 执行副总经理。2011 年 7 月开始从事证券投行业务，具有多年投资银行从业 经验。曾负责及参与了凯众股份、豪悦护理、鼎佳精密等 IPO 项目；参与了 山鹰国际、京新药业等再融资项目。具备良好的专业素养及丰富的项目经验。 浙江京新药业股份有限公司（以下简称"公司"）于近日收到平安证券 股份有限公司（以下简称"平安证券"）出具的《关于更换持续督导保荐代 表人的函》，现将具体情况公告如下 ...

Group 1: IPO Market Activity - The Hong Kong IPO market remained active from February 9 to 15, with 18 companies submitting listing applications, 1 company passing the hearing, and 2 companies completing their public offerings [1] - Six new stocks were listed during this period, with several A-share listed companies initiating "A+H" dual listing processes [1] Group 2: Notable Listings - Haizhi Technology Group (02706.HK) was listed on February 13, with an initial price of HKD 27.06 per share, closing at HKD 92.60 on its first day, marking a 242.20% increase and a market capitalization exceeding HKD 37 billion [4] - The company received a subscription rate of 5065.06 times during the public offering phase and raised approximately HKD 655.4 million [4] Group 3: Company Submissions - Siyuan Electric (002028.SZ) submitted its listing application to the Hong Kong Stock Exchange on February 11, with CITIC Securities as the sole sponsor. The company ranks third among private enterprises in China's power distribution and control equipment market, holding a market share of 3.5% [3] - Other companies that submitted applications include Jingxin Pharmaceutical (002020.SZ) and Xinlitai (002294.SZ), both focusing on central nervous and cardiovascular diseases [3] Group 4: Market Trends - The IPO submissions included companies from various sectors, such as VDL Technology in consumer electronics, Helian Group in bulk commodity services, and Hai Rou Innovation in warehouse robotics [3] - In the biopharmaceutical sector, multiple companies, including Vimo Bio, Yimufeng Bio, Plai Medical, and Noling Bio, also submitted applications [3]

证券之星消息，根据企查查数据显示京新药业（002020）公布了一项国际专利申请，专利名为"药物组 合物"，专利申请号为PCT/CN2025/112343，国际公布日为2026年2月12日。 今年以来京新药业已公布的国际专利申请1个，与去年同期持平。结合公司2025年中报财务数据，2025 上半年公司在研发方面投入了1.85亿元，同比减6.15%。 专利详情如下： 数据来源：企查查 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 图片来源：世界知识产权组织（WIPO） ...

Key Points - Insta360 held its annual meeting where it awarded five sets of properties and several cars to employees, all of whom were born in the 1990s, emphasizing the importance of material incentives alongside recognition [5][6] - The company reported that 2025 was its highest revenue year, with a significant increase in R&D investment, surpassing the total of the previous three years [6] - DeepSeek's recent update has faced backlash from users who feel the model has become less engaging, despite a significant increase in context window capacity [11][12] - AWS has completed layoffs in its Greater China region, affecting approximately 150 employees, primarily in second-tier departments [14][15] - Zhao Ming, former CEO of Honor, has joined Qianli Technology, focusing on AI business models [16] - BMW announced a global recall of multiple models due to a defect in the starter motor that poses a fire risk [56] - Xiaomi's YU7 became the best-selling car in China for January 2026, with a total of 37,869 units sold, significantly outpacing competitors [35][36] - Chery employees expressed dissatisfaction with the company's strict leave policies during the Spring Festival, which limited vacation days [23] - Great Wall Motors announced that its average year-end bonus for 2025 would exceed 50,000 yuan per employee, with a total bonus pool potentially exceeding 42.45 billion yuan [25][26] - Huawei's new vehicle, the Zun Jie S800, will appear on the CCTV Spring Festival Gala, highlighting its market presence [45]

浙江京新药业股份有限公司（以下简称"公司"）已于2026年2月11日向香港联合交易所有限公司（以下 简称"香港联交所"）递交了发行境外上市股份（H股）并在香港联交所主板挂牌上市（以下简称"本次 发行并上市"）的申请，并于同日在香港联交所网站刊登了本次发行并上市的申请资料。该申请资料为 公司按照香港证券及期货事务监察委员会（以下简称"香港证监会"）及香港联交所的要求编制和刊发， 为草拟版本，其所载资料可能会适时作出更新及修订，投资者不应根据其中的资料作出任何投资决定。 鉴于本次发行并上市的认购对象仅限于符合相关条件的境外投资者及依据中国相关法律法规有权进行境 外证券投资的境内合格投资者，公司将不会在境内证券交易所的网站和符合境内监管机构规定条件的媒 体上刊登该申请资料，但为使境内投资者及时了解该等申请资料披露的本次发行并上市以及公司的其他 相关信息，现提供该申请资料在香港联交所网站的查询链接供查阅： 中文： 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗漏。 浙江京新药业股份有限公司 董事会 2026年2月12日 http ...

资料显示，京新药业为一家以创新为驱动力的制药集团，重点专注于两大核心疾病领域：中枢神经系统 疾病、心血管及脑血管疾病。 京新药业发展轨迹紧随过去30年中国制药产业的演进，该公司最初专注于中间体与原料药领域，随后将 业务向下游延伸至药物领域。近年来，京新药业开始向创新药方向转型。 京新药业在申请材料中提到，公司既有的商业化业务为创新药物的研发与商业化提供可持续的技术、市 场及财务支持。财务数据方面，2024年，京新药业总收入为41.59亿元，净利为7.19亿元，研发投入约 3.84亿元。京新药业方面表示，公司计划持续维持相当高水平的研发投资，以推进创新战略，并促进成 长。 2月12日早间，京新药业在A股公告，公司已向中国香港联交所递交上市申请，这家最早专注于中间体 与原料药领域，又随着时代发展向创新药转型的老牌药企，正式踏上"A+H"两地上市的旅程。据北京商 报记者不完全统计，今年开年40余日，已有约30家医药企业递表港交所。 药企扎堆赴港，"创新"成为关键词。上述30家企业中，13家为带有特殊标识"B"的未盈利的创新药、创 新医疗器械企业。港交所对未盈利生物科技企业的上市审核，始终锚定产品的创新性、管线的差异 ...